glp-1 ncbi Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands GLP-1 Agonists For Obesity In

Most side effects occur after the initial dose and can last as long as the second dose

Both groups lost weight early, but separation emerged between weeks 48

Glucagon-like peptide 1 (GLP-1) is a peptide hormone and growth factor that has shown neuroprotective effects in preclinical studies, and the success of GLP-1 mimetics in phase II clinical trials in AD and PD has raised new hope

And the psychological impact of timing, knowing when to expect effects and when they will fade, shapes adherence more than most people realize

At the same time, withholding GLP-1RAs in the perioperative period is not without risk, as it may lead to suboptimal glycaemic control and loss of the cardiometabolic benefits associated with continued therapy [28, 42]